Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923278 | 0.79 | CDK2 (0.41) | CDK2EPHB3ALDH1A1 | |
| SCHEMBL12875621 | 0.79 | CDK2 (0.41) | CDK2EPHB3MAP2K1 | |
| SCHEMBL1160399 | 0.79 | CDK2 (0.49) | CDK2EPHB3MAP2K1ALDH1A1 | |
| SCHEMBL12681980 | 0.71 | CDK2 (0.35) | CDK2 | |
| SCHEMBL9923342 | 0.70 | CDK2 (0.40) | CDK2EPHB3 | |
| SCHEMBL9923306 | 0.69 | CDK2 (0.35) | CDK2ALDH1A1ELANE | |
| SCHEMBL9923309 | 0.68 | CDK2 (0.33) | CDK2EPHB3 | |
| SCHEMBL16383076 | 0.68 | MAP2K1 (0.33) | CDK2MAP2K1ALDH1A1 | |
| SCHEMBL1693953 | 0.68 | CDK2 (0.49) | CDK2EPHB3ALDH1A1ELANE | |
| SCHEMBL9923104 | 0.68 | CDK2 (0.31) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013033093-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | CDK2 423/4885EPHB3 3982/4885MAP2K1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.